Search Results

In partnership with GentiBio, BMS aims to harness the capabilities of engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with IBD.

GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cell (Tregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced that the company will participate in two upcoming investor conferences.

GentiBio, Inc., a biotherapeutics company developing engineered regulatory T cells therapies for autoimmunity, autoinflammation and allergic diseases, announced that Neely Mozaffarian, M.D., Ph.D., has been appointed to the position of Chief Medical Officer.

GentiBio, Inc. today announced the appointment of Chuck Silberstein , M.D., MBA, as Chief Financial Officer (CFO).

GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmunity, autoinflammation and allergic diseases, today announced an upcoming presentation of preclinical data relating to the company’s platform technology.

GentiBio, Inc., an engineered regulatory T cells (Tregs) company, announced today that it has entered into a collaboration with Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD).

GentiBio, Inc. announced a strategic development and manufacturing partnership today to advance GentiBio’s unique immune tolerance platform.

GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmune, auto-inflammatory, alloimmune and allergic diseases, today announced the release of preclinical data demonstrating a novel approach for using engineered Tregs to potentially treat and prevent type 1 diabetes (T1D).

GentiBio focuses on engineered regulatory T-cells (EngTregs) to treat autoimmune, alloimmune, autoinflammatory and allergic diseases.